BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis
BVXVDelisted Stock | USD 1.35 0.03 2.17% |
Slightly above 61% of BiondVax Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in BiondVax Pharmaceuticals suggests that many traders are alarmed regarding BiondVax Pharmaceuticals' prospects. BiondVax Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, BiondVax Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
BiondVax |
Broad-based collaboration with Max Planck and University Medical Center Gottingen yields attractive anti-IL-17 VHH antibodies includes exclusive worldwide license for all potential indications, beginning with
Read at benzinga.com
BiondVax Pharmaceuticals Fundamental Analysis
We analyze BiondVax Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BiondVax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BiondVax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Liabilities
Current Liabilities Comparative Analysis
BiondVax Pharmaceuticals is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
BiondVax Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BiondVax Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of BiondVax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BiondVax Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
BiondVax Pharmaceuticals Related Equities
ADTX | Aditxt | 5.56 | ||||
GOVX | GeoVax Labs | 4.68 | ||||
ARMP | Armata Pharmaceuticals | 4.46 | ||||
ANTX | AN2 Therapeutics | 4.35 | ||||
ATXI | Avenue Therapeutics | 4.30 | ||||
CANF | Can Fite | 3.95 | ||||
SABS | SAB Biotherapeutics | 1.95 | ||||
SLRX | Salarius Pharmaceuticals | 0.60 | ||||
ORMP | Oramed Pharmaceuticals | 0.42 | ||||
MOLN | Molecular Partners | 0.19 | ||||
PHVS | Pharvaris | 0.36 | ||||
MLYS | Mineralys Therapeutics, | 0.39 | ||||
MDWD | Mediwound | 0.73 | ||||
VCNX | Vaccinex | 0.91 | ||||
KTTA | Pasithea Therapeutics | 2.15 | ||||
ADIL | Adial Pharmaceuticals | 2.86 | ||||
RVPH | Reviva Pharmaceuticals | 3.23 | ||||
BLRX | BioLineRx | 4.35 | ||||
RNAZ | Transcode Therapeutics | 5.66 | ||||
SRZN | Surrozen | 5.95 | ||||
PEPG | PepGen | 8.41 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in BiondVax Stock
If you are still planning to invest in BiondVax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BiondVax Pharmaceuticals' history and understand the potential risks before investing.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Stocks Directory Find actively traded stocks across global markets | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |